Clinical Trial Update: CD30 CAR-T in the Treatment of CD30 Positive Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating a CD30-targeted CAR-T therapy for CD30-positive lymphomas is listed as not yet recruiting, sponsored by Shandong Qilu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Cd30-positive Peripheral T-cell Lymphoma
• Lymphoma

Drugs mentioned

• CD30 CAR-T

Snippet

Sponsor: Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | Conditions: Lymphoma, B Cell Lymphoma | EARLY_Phase 1 | Status: NOT_YET_RECRUITING